Identification of early cognitive change in diverse African populations. A harmonisation consortium to inform future dementia prevention studies.

识别不同非洲人群的早期认知变化。

基本信息

  • 批准号:
    MR/X03092X/1
  • 负责人:
  • 金额:
    $ 49.53万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2023
  • 资助国家:
    英国
  • 起止时间:
    2023 至 无数据
  • 项目状态:
    未结题

项目摘要

This study will benefit older people living in Africa who are at risk of getting dementia, specifically Alzheimer's disease, the most common type of dementia worldwide. Over two thirds of people with dementia worldwide live in countries classified as 'low and middle income'. These 'low and middle income' countries have lower resources per person to cope with the challenges of dementia. This includes most African countries, where numbers of people with dementia are growing rapidly, because people are living longer due to better healthcare. We know that up to four in ten dementias could be prevented. Despite this, almost all research on how to prevent dementia has been done in and for, 'high income' countries like the UK. The earliest changes of Alzheimer's disease happen years prior to diagnosis. By the time there is obvious memory difficulty, the underlying brain damage is widespread and may be irreversible. Researchers have started to create ways of measuring these earliest changes through tests of brain functions which may be affected earlier than memory. These include tests of language, and one's ability to find one's way (navigation). Currently, we do not have tests to identify these early Alzheimer's disease changes in older people in Africa. It is well-known that culture and education affect performance on cognitive tests, and that measures designed in high income countries are unlikely to work well. We need African tests of the brain functions we know to be affected in early Alzheimer's disease, that are comparable to high-income country tests so that joint studies can be conducted. This study will create a formal partnership of community groups, people with dementia, Ministry of Health representatives, and academic researchers with experience of designing tests for early Alzheimer's disease in other countries to address these issues. In Tanzania, we will collaborate with local communities and dementia groups to evaluate existing tests of the brain functions affected earliest in Alzheimer's disease, adapt these tests to be acceptable to them and agree on how best to explain tests to older people so that they feel comfortable trying them. We will conduct a series of validation studies in hospital clinics and in a rural community, comparing performance on our adapted early tests to existing dementia tests used in Africa and with clinical diagnosis of Alzheimer's disease by a specialist doctor. Working with volunteers, communities, and the Tanzanian Ministry of Health, we will investigate what the normal test scores should be for an older person in Tanzania. We will ask over 700 people aged 60 and over to volunteer at Government health promotion events, and produce data on test performance by age, educational level, sex, and geographical location. We will work with another population study in Kilimanjaro, to use census data to help us establish a community baseline study and pilot follow-up to find out if our tests are likely to be feasible and useful in studies of change over time. Once we have properly evaluated the tests in Tanzania, the African Dementia Consortium network will repeat our work on normal test scores in their individual countries by training early career researchers. This additional work is planned for Benin, Ethiopia, Kenya, Uganda, Nigeria, Ghana, and Mozambique. This work will help our partnership of researchers to develop a future African dementia prevention study. This work may later also benefit researchers who work with minority populations in the UK. Our goal is to publish a set of effective tests, which other researchers can easily use. We want African older people to be able to take part in global dementia prevention studies wherever they live so that they have sound information on how to reduce their risk. Having firm evidence that African early Alzheimer's disease tests exist and are useful is the first step in making this happen.
这项研究将使生活在非洲的老年人受益,他们有患痴呆症的风险,特别是阿尔茨海默病,这是世界上最常见的痴呆症。全世界超过三分之二的痴呆症患者生活在被归类为“低收入和中等收入”的国家。这些“低收入和中等收入”国家科普痴呆症挑战的人均资源较低。这包括大多数非洲国家,痴呆症患者的数量正在迅速增长,因为人们的寿命更长,因为更好的医疗保健。我们知道高达十分之四的痴呆症是可以预防的。尽管如此,几乎所有关于如何预防痴呆症的研究都是在英国等“高收入”国家进行的。阿尔茨海默病的最早变化发生在诊断前几年。当出现明显的记忆困难时,潜在的脑损伤是广泛的,可能是不可逆的。研究人员已经开始通过测试大脑功能来测量这些最早的变化,这些功能可能比记忆更早受到影响。这些包括语言测试,和一个人的能力,找到一个人的方式(导航)。目前,我们还没有测试来确定非洲老年人的这些早期阿尔茨海默病变化。众所周知,文化和教育影响认知测试的表现,而高收入国家设计的措施不太可能奏效。我们需要非洲对我们所知的早期阿尔茨海默病患者的大脑功能进行测试,这些测试可以与高收入国家的测试相媲美,以便进行联合研究。这项研究将建立社区团体、痴呆症患者、卫生部代表和具有在其他国家设计早期阿尔茨海默病测试经验的学术研究人员的正式伙伴关系,以解决这些问题。在坦桑尼亚,我们将与当地社区和痴呆症团体合作,评估阿尔茨海默病最早影响的大脑功能的现有测试,调整这些测试以使他们能够接受,并就如何最好地向老年人解释测试达成一致,以便他们感到舒适尝试它们。我们将在医院诊所和农村社区进行一系列验证研究,将我们改编的早期测试的性能与非洲使用的现有痴呆症测试进行比较,并与专科医生对阿尔茨海默病的临床诊断进行比较。我们将与志愿者、社区和坦桑尼亚卫生部合作,调查坦桑尼亚老年人的正常测试分数。我们将邀请700多名60岁及以上的人参加政府的健康促进活动,并按年龄、教育水平、性别和地理位置提供测试成绩数据。我们将与基利曼哈罗的另一项人口研究合作,利用人口普查数据帮助我们建立社区基线研究和试点后续行动,以确定我们的测试是否可能在研究随时间推移的变化中可行和有用。一旦我们对坦桑尼亚的测试进行了适当的评估,非洲痴呆症联盟网络将通过培训早期职业研究人员,在他们各自的国家重复我们对正常测试分数的工作。计划为贝宁、埃塞俄比亚、肯尼亚、乌干达、尼日利亚、加纳和莫桑比克开展这项额外工作。这项工作将有助于我们的研究人员合作开发未来的非洲痴呆症预防研究。这项工作以后也可能使在英国从事少数民族工作的研究人员受益。我们的目标是发布一套有效的测试,其他研究人员可以很容易地使用。我们希望非洲老年人能够参与全球痴呆症预防研究,无论他们居住在哪里,这样他们就可以获得如何降低风险的可靠信息。有确凿的证据表明,非洲早期阿尔茨海默病测试的存在和有用的是第一步,使之成为现实。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stella-Maria Paddick其他文献

Clinical and research implications of the findings of the Tanzania 2022 Population and Housing Census for the development and suitability of neuropsychological tests for older adults in Tanzania
  • DOI:
    10.1186/s12877-025-06071-9
  • 发表时间:
    2025-05-30
  • 期刊:
  • 影响因子:
    3.800
  • 作者:
    Damas Andrea Mlaki;Victor Valcour;Andjelika Milicic;Elaine Allen;Stella-Maria Paddick;Aaron Berkowitz;Raina Kiama;Bruce Miller
  • 通讯作者:
    Bruce Miller
Feasibility and Acceptability Findings From a Pilot Study of the Adapted Ziba Ufa Intervention for Late Life Depression and Chronic Conditions in Tanzania
  • DOI:
    10.1016/j.osep.2024.11.001
  • 发表时间:
    2025-03-01
  • 期刊:
  • 影响因子:
  • 作者:
    Sophie Walker;Lucy J Robinson;Lisbeth Mhando;Stella-Maria Paddick;Judith Boshe;R. Hamish McAllister-Williams;Wilson Eliamini;Linus Sakanda;Richard Walker
  • 通讯作者:
    Richard Walker
Screening tools for common mental disorders in older adults in South Asia: a systematic scoping review
南亚老年人常见精神障碍筛查工具:系统范围审查
  • DOI:
    10.1017/s1041610220003804
  • 发表时间:
    2022-05-01
  • 期刊:
  • 影响因子:
    4.300
  • 作者:
    Lachlan Fotheringham;Stella-Maria Paddick;Evelyn Barron Millar;Claire Norman;Ammu Lukose;Richard Walker;Mathew Varghese
  • 通讯作者:
    Mathew Varghese
Posthospitalization COVID-19 cognitive deficits at 1 year are global and associated with elevated brain injury markers and gray matter volume reduction
住院后 1 年的 COVID-19 认知缺陷是全球性的,并且与脑损伤标志物升高和灰质体积减少有关
  • DOI:
    10.1038/s41591-024-03309-8
  • 发表时间:
    2024-09-23
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Greta K. Wood;Brendan F. Sargent;Zain-Ul-Abideen Ahmad;Kukatharmini Tharmaratnam;Cordelia Dunai;Franklyn N. Egbe;Naomi H. Martin;Bethany Facer;Sophie L. Pendered;Henry C. Rogers;Christopher Hübel;Daniel J. van Wamelen;Richard A. I. Bethlehem;Valentina Giunchiglia;Peter J. Hellyer;William Trender;Gursharan Kalsi;Edward Needham;Ava Easton;Thomas A. Jackson;Colm Cunningham;Rachel Upthegrove;Thomas A. Pollak;Matthew Hotopf;Tom Solomon;Sarah L. Pett;Pamela J. Shaw;Nicholas Wood;Neil A. Harrison;Karla L. Miller;Peter Jezzard;Guy Williams;Eugene P. Duff;Steven Williams;Fernando Zelaya;Stephen M. Smith;Simon Keller;Matthew Broome;Nathalie Kingston;Masud Husain;Angela Vincent;John Bradley;Patrick Chinnery;David K. Menon;John P. Aggleton;Timothy R. Nicholson;John-Paul Taylor;Anthony S. David;Alan Carson;Ed Bullmore;Gerome Breen;Adam Hampshire;Benedict D. Michael;Stella-Maria Paddick;E. Charles Leek
  • 通讯作者:
    E. Charles Leek

Stella-Maria Paddick的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似国自然基金

Crocin 抑制 Hartley 豚鼠早期骨关节炎发生的 作用机制研究
  • 批准号:
    TGD24H060003
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
RIPK3蛋白及其RHIM结构域在脓毒症早期炎症反应和脏器损伤中的作用和机制研究
  • 批准号:
    82372167
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
均相液相生物芯片检测系统的构建及其在癌症早期诊断上的应用
  • 批准号:
    82372089
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
环境抗雄激素干预AR/TGFB1I1致尿道下裂血管内皮细胞发育异常的机制及其“预警信号”在早期诊断中的价值
  • 批准号:
    82371605
  • 批准年份:
    2023
  • 资助金额:
    46.00 万元
  • 项目类别:
    面上项目
增强子在小鼠早期胚胎细胞命运决定中的功能和调控机制研究
  • 批准号:
    82371668
  • 批准年份:
    2023
  • 资助金额:
    52.00 万元
  • 项目类别:
    面上项目
BNIP-2调控E-cadherin细胞内分选运输的机制研究
  • 批准号:
    32100540
  • 批准年份:
    2021
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
玉米Edk1(Early delayed kernel 1)基因的克隆及其在胚乳早期发育中的功能研究
  • 批准号:
    31871625
  • 批准年份:
    2018
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
膀胱癌高表达基因UPK3A的筛选、鉴定和相关研究
  • 批准号:
    81101922
  • 批准年份:
    2011
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
精神创伤相关的抑郁症HPA轴功能与相关脑区磁共振特征研究
  • 批准号:
    81171286
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
早年心理应激对大鼠抑郁样行为及突触可塑性的影响
  • 批准号:
    81171284
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目

相似海外基金

Identification of Prospective Predictors of Alcohol Initiation During Early Adolescence
青春期早期饮酒的前瞻性预测因素的鉴定
  • 批准号:
    10823917
  • 财政年份:
    2024
  • 资助金额:
    $ 49.53万
  • 项目类别:
Identification and optimization of verapamil as a novel neuroprotective and anti-inflammatory agent for reducing long-term neurological morbidities following organophosphate-induced status epilepticus
维拉帕米作为新型神经保护和抗炎剂的鉴定和优化,用于减少有机磷引起的癫痫持续状态后的长期神经系统发病率
  • 批准号:
    10727765
  • 财政年份:
    2023
  • 资助金额:
    $ 49.53万
  • 项目类别:
Identification of Distinct Biotypes in Clinical High Risk for Psychosis State Using Objective Brain-Based Biomarkers
使用客观的脑基生物标志物识别临床高风险精神病状态的不同生物型
  • 批准号:
    10646765
  • 财政年份:
    2023
  • 资助金额:
    $ 49.53万
  • 项目类别:
Early Identification Of Developmental Delay Among Infants And Toddlers With Sickle Cell Disease
早期识别患有镰状细胞病的婴儿和幼儿发育迟缓
  • 批准号:
    10590311
  • 财政年份:
    2023
  • 资助金额:
    $ 49.53万
  • 项目类别:
Imaging biomarkers for early identification of mTBI patients at risk for persistent post-concussive symptoms.
成像生物标志物用于早期识别有持续性脑震荡后症状风险的 mTBI 患者。
  • 批准号:
    478019
  • 财政年份:
    2023
  • 资助金额:
    $ 49.53万
  • 项目类别:
    Operating Grants
Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM sleep Behavior Disorder
血清素诱导的快速眼动睡眠行为障碍中前驱神经变性的鉴定
  • 批准号:
    10734350
  • 财政年份:
    2023
  • 资助金额:
    $ 49.53万
  • 项目类别:
Barriers to early identification of dementia in a safety net healthcare system
安全网医疗保健系统中早期识别痴呆症的障碍
  • 批准号:
    10728164
  • 财政年份:
    2023
  • 资助金额:
    $ 49.53万
  • 项目类别:
Application of a Bayesian strategy to ABCD: Identification of substance use risk and COVID-19 effects on neurodevelopment
贝叶斯策略在 ABCD 中的应用:识别物质使用风险和 COVID-19 对神经发育的影响
  • 批准号:
    10365250
  • 财政年份:
    2022
  • 资助金额:
    $ 49.53万
  • 项目类别:
Improving identification of HIV-associated neurocognitive disorder (HAND) in Latin America: A multimodal approach to HAND in Peru
改善拉丁美洲 HIV 相关神经认知障碍 (HAND) 的识别:秘鲁针对 HAND 的多模式方法
  • 批准号:
    10654864
  • 财政年份:
    2022
  • 资助金额:
    $ 49.53万
  • 项目类别:
Identification of endophenotypes associated with Alzheimer’s disease progression in Hispanic population
鉴定与西班牙裔人群中阿尔茨海默病进展相关的内表型
  • 批准号:
    10448860
  • 财政年份:
    2022
  • 资助金额:
    $ 49.53万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了